Related Experiment Video
Updated: Jul 26, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Low-molecular-weight heparins for acute coronary syndromes: an emergency medicine perspective
1Medical College of Virginia, Virginia Commonwealth University, Richmond 23298, USA.
Insights
Emergency departments face challenges managing chest pain patients. Low-molecular-weight heparins offer clinical and economic benefits over unfractionated heparins for specific heart conditions.
Area of Science:
- Cardiology
- Emergency Medicine
- Pharmacology
Background:
- Chest pain patients are a significant challenge for emergency departments.
- Current diagnostic and treatment methods have major clinical and financial impacts.
- Critical pathways are essential for efficient patient management.
Purpose of the Study:
- To evaluate the role of low-molecular-weight heparins in managing chest pain.
- To compare low-molecular-weight heparins with unfractionated heparins.
- To highlight clinical and economic advantages of specific anticoagulant therapies.
Main Methods:
- Review of diagnostic and treatment modalities for emergency department chest pain.
- Analysis of critical pathway implementation.
- Assessment of low-molecular-weight heparins versus unfractionated heparins.
Main Results:
- Low-molecular-weight heparins demonstrate clinical advantages.
- Economic benefits favor low-molecular-weight heparins.
- Unfractionated heparins are less advantageous in specific scenarios.
Conclusions:
- Low-molecular-weight heparins are increasingly important in managing unstable angina and non-Q wave myocardial infarction.
- These agents offer superior clinical outcomes and cost-effectiveness.
- Optimized critical pathways incorporating LMWH improve patient care and resource utilization.
Abstract:
Patients with chest pain represent one of the largest and most challenging populations for emergency departments to treat. Diagnostic and treatment modalities implemented in the emergency department are associated with significant clinical outcomes and financial implications. Critical pathways are being developed to increase the speed and efficiency with which these patients are managed. Of particular importance is the evolving role of low-molecular-weight heparins, which have both clinical and economic advantages over unfractionated heparins in treating unstable angina and non-Q wave myocardial infarction.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome IV: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

